41094-88-6

Basic information

• Product Name: 4-(BUTYLAMINO)-1-ETHYL-6-METHYL 1H-PYRAZOLO[3,4B]PYRIDINE-5-ETHYLCARBOXYLATE HYDROCHLORIDE
• Synonyms: TRACAZOLATE HYDROCHLORIDE;4-(BUTYLAMINO)-1-ETHYL-6-METHYL 1H-PYRAZOLO[3,4B]PYRIDINE-5-ETHYLCARBOXYLATE HYDROCHLORIDE;TRACAZOLATE NON-BENZODIAZEPINE AN;TracazolateHCl;ICI-136753;Ethyl 4-(butylamino)-1-ethyl-6-methyl-1h-pyrazolo[3,4-b]pyridine-5-carboxylate
• CAS NO: 41094-88-6
• Molecular Formula: C₁₆H₂₄N₄O₂
• Molecular Weight: 304.39
• EINECS: 255-214-9
• Mol File: 41094-88-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 73.5-75 °C
• Boiling Point: 419.5°Cat760mmHg
• Flash Point: 207.5°C
• Appearance: white/solid
• Density: 1.17g/cm³
• Vapor Pressure: 3.01E-07mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: Desiccate at RT
• Solubility: 0.1 M HCl: soluble
• PKA: 5.01±0.10(Predicted)
• CAS DataBase Reference: 4-(BUTYLAMINO)-1-ETHYL-6-METHYL 1H-PYRAZOLO[3,4B]PYRIDINE-5-ETHYLCARBOXYLATE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(BUTYLAMINO)-1-ETHYL-6-METHYL 1H-PYRAZOLO[3,4B]PYRIDINE-5-ETHYLCARBOXYLATE HYDROCHLORIDE(41094-88-6)
• EPA Substance Registry System: 4-(BUTYLAMINO)-1-ETHYL-6-METHYL 1H-PYRAZOLO[3,4B]PYRIDINE-5-ETHYLCARBOXYLATE HYDROCHLORIDE(41094-88-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 41094-88-6(Hazardous Substances Data)

Usage

Uses

Tracazolate Hydrochloride is a useful intermediate and pharmacological compound.

Biological Activity

Subtype-selective GABA A receptor modulator. Can potentiate or inhibit recombinant GABA A function depending on subunit combination. Enhances native GABA A receptor function and is anxiolytic following systemic administration in vivo .

InChI:InChI=1/C16H24N4O2/c1-5-8-9-17-14-12-10-18-20(6-2)15(12)19-11(4)13(14)16(21)22-7-3/h10H,5-9H2,1-4H3,(H,17,19)

Upstream product

• 3528-58-3 5-Amino-1-ethylpyrazole 
• 41095-06-1 1-ethyl-6-methyl-4-oxo-4,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 
• 570-08-1 diethyl acetylmalonate 
• 109-73-9 N-butylamine 
• 41095-07-2 4-chloro-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 

Relevant articles and documents

METHODS AND TOOLS FOR THE THERAPY OF NEURODEGENERATIVE PATHOLOGIES

The present invention concerns compositions and methods for the treatment of neurodegenerative diseases in which the cognitive functions are altered, such as observed in Alzheimer's disease. More particularly, the invention presents a strategy for human clinical monitoring of the activity and/or effectiveness of neuroprotective treatments, based on biochemical assay of certain platelet parameters, and thus can be done by blood sampling. The invention also concerns methods, tools, constructions and compositions suitable for implementing these strategies

Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents

A series of 1-substituted 4-amino-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid esters and amides were synthesized and screened for anxiolytic activity in the shock-induced suppression of drinking (SSD) test. The compounds were also tested for their ability to displace [3H]flunitrazepam (FLU) from brain benzodiazepine (BZ) binding sites. Many compounds were active in these screens and, additionally, demonstrated a selectivity for the type 1 BZ (BZ1) receptor over the type 2 BZ (BZ2) receptor as indicated by Hill coefficients significantly less than unity and analysis of [3H]FLU binding results from different brain regions. Based on the results of structure-activity studies of these compounds, a hypothesis was proposed to explain the structural features necessary for optimal interaction with brain BZ receptors. A detailed pharmacological evaluation of one of the most potent behaviorally active compounds (27) demonstrated it to be BZ1 selective; also, in comparison to diazepam, 27 showed minimal sedative and alcohol interactive properties at therapeutically effective doses.